Development of Engager T cells for immunotherapy of lung cancer

Research Project

Project/Area Number	15K09218
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Respiratory organ internal medicine
Research Institution	Osaka University
Principal Investigator	IWAHORI KOTA 大阪大学, 医学系研究科, 特任講師(常勤) (80566448)
Project Period (FY)	2015-10-21 – 2018-03-31
Project Status	Completed (Fiscal Year 2017)
Budget Amount *help	¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000) Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000) Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000) Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Keywords	がん免疫療法
Outline of Final Research Achievements	We generated T cells expressing a secretable bispecific T-cell engager (Engager-T cells) for cancer immunotherapy. For the development of Engager T cells against lung cancer, we evaluated detailed immunological aspects in clinical specimens from non-small cell lung cancer (NSCLC) patients. We analyzed the immune profiles and T cell cytotoxicity of lung tumor tissue from NSCLC patients. By using bispecific T-cell engager (BiTE) to assess the cytotoxicity of T cells, we found that the cytotoxicity of tumor-infiltrated T cells correlated with immune profiles and smoking status of NSCLC patients. These results imply predictive biomarkers for the efficacy of Engager-T cells.

Report

(4 results)